Oncoarendi Therapeutics won over 25.5 million zloty
Oncoarendi Therapeutics as the leader of an academic – industrial consortium won over 25.5 million zloty in the second call for proposals of the National Center of Research and Development in the StrategMed program. The aim of this project is to develop a conceptually novel therapeutic approach in cancer treatment – small molecule immune-modulators to knock-down the ability of tumors to escape immune surveillance. The project was ranked second among twelve proposals recommended for funding and a total of one hundred and nine evaluated project proposals.
The consortium partners include Medical University of Warsaw, Nencki Institute of Experimental Biology, Institute of Biochemistry and Biophysics, International Institute of Molecular and Cell Biology, commercial partners – Nanovelos Ltd, Scanmed Hospital of St. Rafael, as well as subcontractors – Military Institute of Medicine, Oxford University, Weatherall Institute of Molecular Medicine.